Gene-terapiaikuspegi terapeutiko berria begietako gaitzen tratamenduan

  1. Julen Rodríguez Castejón
  2. Itziar Gómez Aguado
  3. Mónica Vicente Pascual
  4. Alicia Rodríguez Gascón
  5. Arantxazu Isla Ruiz
  6. María Ángeles Solinís Aspiazu
  7. Ana del Pozo Rodríguez
Revista:
Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria

ISSN: 0214-9001

Año de publicación: 2019

Número: 36

Páginas: 31-48

Tipo: Artículo

Otras publicaciones en: Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria

Resumen

Gene therapy has emerged as a promising tool for disorders that have no cure. It consists in the administration of therapeutic nucleic acids into patients for treating diseases. The success of gene therapy relies on the efficient delivery of the genetic material to target cells. Among gene delivery systems, viral vectors have been widely used due to their good gene transference efficacy. However, their potential risk associated with immunogenicity and mutagenesis has promoted the design of non-viral vectors. Non-viral vectors are safer and easier to produce, but their main limitation remains lower transfection efficacy. An attractive candidate for gene therapy is the eye, since it is easily accessible, easily examined and relatively immune privileged. Only 1,3% of all gene therapy clinical trials treat ocular disorders, but they have shown great potential in recent years. In fact, in 2018 the Food and Drug Administration and the European Medicine Agency approved the commercialization of the first gene therapy based ocular drug, Luxturna®, for the treatment of Leber Congenital Amaurosis. In this review, we present the main administration routes to eye, gene therapy strategies and ocular barriers to overcome for successful gene transfer. Different ocular disease candidates to be treated by gene therapy are also reviewed. The efforts and advances made in the field of gene therapy have led to the development of new drugs to treat eye diseases. Many of them are still being evaluated in clinical trials, but some have already reached the market and patients.